Benefit-risk assessment of bevacizumab in the treatment of breast cancer

Drug Safety

Volumn 35, Issue 1, 2012, Pages 15-25

  Dienstmann, Rodrigo ^a   Ades, Felipe ^b   Saini, Kamal S ^b   Metzger Filho, Otto ^b  

^a VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^b JULES BORDET INSTITUTE   (Belgium)

Author keywords

Benefit risk assessment; Bevacizumab; Breast cancer

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; NAVELBINE; PACLITAXEL; PLACEBO;

ADVANCED CANCER; BLEEDING; BREAST CANCER; CANCER ADJUVANT THERAPY; CONGESTIVE HEART FAILURE; DIGESTIVE SYSTEM PERFORATION; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; HYPERTENSION; INFECTION; META ANALYSIS (TOPIC); MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; REVIEW; RISK BENEFIT ANALYSIS; VENOUS THROMBOEMBOLISM;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BREAST NEOPLASMS; FEMALE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 83055165638     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11595910-000000000-00000     Document Type: Review

References (49)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971 Nov; 285 (21): 1182-6
2. Ortholan C, Durivault J, Hannoun-Levi JM, et al. Bevacizumab/docetaxel association is more efficient than docetaxel alone in reducing breast and prostate cancer cell growth: a new paradigm for understanding the therapeutic effect of combined treatment. Eur J Cancer 2010 Nov; 46 (16): 3022-36
3. Sweeney CJ, Miller KD, Sissons SE, et al. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res 2001 Apr; 61 (8): 3369-72 (Pubitemid 32695027)
4. Cobleigh MA, Langmuir VK, Sledge GW, et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Seminars Oncol 2003 Oct; 30 (5 Suppl. 16): 117-24 (Pubitemid 37433402)
5. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007 Dec; 357 (26): 2666-76
6. Miles DW, Chan A, Dirix LY, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010 Jul; 28 (20): 3239-47
7. Robert NJ, Dieras V, Glaspy J, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011; 29: 1252-60
8. Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005 Feb; 23 (4): 792-9 (Pubitemid 46224178)
9. Brufsky AM, Hurvitz S, Perez E, et al. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negativemetastatic breast cancer. J Clin Oncol 2011 Nov 10; 29 (32): 4286-93
10. Gray R, Bhattacharya S, Bowden C, et al. Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol 2009 Oct; 27 (30): 4966-72
11. Allison M. Avastin's commercial march suffers setback. Nature Biotechnol 2010 Sep; 28 (9): 879-80
12. US Food and Drug Administration, US Department of Health and Human Services. Postmarket drug safety information for patients and providers: Avastin (bevacizumab) information [online]. Available from URL: http://www.fda.gov/ Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatients andProviders/ UCM193900 [Accessed 2011 Jun 29]
13. Smith IE, Pierga JY, Biganzoli L, et al. First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2251 patients. Ann Oncol 2010 Mar; 22 (3): 595-602
14. Valachis A, Polyzos NP, Patsopoulos NA, et al. Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials. Breast Cancer Res Treat 2010 Jul; 122 (1): 1-7
15. Lee JB, Woo OH, Park KH, et al. Bevacizumab for salvage treatment of metastatic breast cancer: a systemic review and meta-analysis of randomized controlled trials. Invest New Drugs 2011 Feb; 29 (1): 182-8
16. Chan A, Miles DW, Pivot X. Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer. Ann Oncol 2010 Dec; 21 (12): 2305-15
17. von Minckwitz G, Eidtmann H, Rezai M, et al. Neoadjuvant chemotherapy with or without bevacizumab: primary efficacy endpoint analysis of the GEPARQUINTO Study (GBG 44) [abstract no. S4-6]. San Antonio Breast Cancer Symposium; 2010 Dec 8-12; San Antonio (TX)
18. An MM, Zou Z, Shen H, et al. Incidence and risk of significantly raised blood pressure in cancer patients treated with bevacizumab: an updated meta-analysis. Eur J Clin Pharmacol 2010 Aug; 66 (8): 813-21
19. Hapani S, Sher A, Chu D, et al. Increased risk of serious hemorrhage with bevacizumab in cancer patients: a metaanalysis. Oncology 2010; 79 (1-2): 27-38
20. Khasraw M, Holodny A, Goldlust SA, et al. Intracranial hemorrhage in patients with cancer treated with bevacizumab: the Memorial Sloan-Kettering experience. Ann Oncol. Epub 2011 May 4
21. Nalluri SR, Chu D, Keresztes R, et al. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 2008 Nov; 300 (19): 2277-85
22. Ranpura V, Hapani S, Chuang J, et al. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials. Acta Oncol 2010 Apr; 49 (3): 287-97
23. Schutz FA, Je Y, Azzi GR, et al. Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes. Ann Oncol 2011 Jun; 22 (6): 1404-12
24. Choueiri TK, Mayer EL, Je Y, et al. Congestive heart failure risk in patients with breast cancer treated with bevacizumab. J Clin Oncol 2011 Feb; 29 (6): 632-8
25. Hapani S, Chu D, Wu S. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a metaanalysis. Lancet Oncol 2009 Jun; 10 (6): 559-68
26. Ranpura V, Hapani S, Wu S. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA 2011 Feb; 305 (5): 487-94
27. von Minckwitz G, Eidtmann H, Loibl S, et al. Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial. Ann Oncol 2011 Feb; 22 (2): 301-6
28. Guarneri V, Miles D, Robert N, et al. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Res Treat 2010 Jul; 122 (1): 181-8
29. Zhuang SH, Xiu L, Elsayed YA. Overall survival: a gold standard in search of a surrogate: the value of progressionfree survival and time to progression as end points of drug efficacy. Cancer J 2009 Sep-Oct; 15 (5): 395-400
30. Saad ED, Katz A, Hoff PM, et al. Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature. Ann Oncol 2010 Jan; 21 (1): 7-12
31. Lebwohl D, Kay A, Berg W, et al. Progression-free survival: gaining on overall survival as a gold standard and accelerating drug development. Cancer J 2009 Sep-Oct; 15 (5): 386-94
32. Ocaña A, Amir E, Vera F, et al. Addition of bevacizumab to chemotherapy for treatment of solid tumors: similar results but different conclusions. J Clin Oncol 2011 Jan; 29 (3): 254-6
33. Fojo T, Wilkerson J. Bevacizumab and breast cancer: the E2100 outlier. Lancet Oncol 2010 Dec; 11 (12): 1117-9
34. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004 Jun; 350 (23): 2335-42 (Pubitemid 38702844)
35. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006 Dec; 355 (24): 2542-50 (Pubitemid 44917502)
36. Morris PG, Dickler M, McArthur H, et al. Adjuvant dosedense doxorubicin-cyclophosphamide x 4 with or without bevacizumab is safe: no evidence of short-term changes in left ventricular ejection fraction [abstract no. 4102]. Cancer Res 2009; 69 (2 Suppl. 1): 281S
37. McArthurHL, RugoH, Nulsen B, et al.A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer. Clin Cancer Res 2011; 17: 3398-407
38. Miller KD, O'Neill A, Perez EA, et al. A phase II pilot trial incorporating bevacizumab into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node positive breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group. Ann Oncol. Epub 2011 Aug 4
39. Eastern Cooperative Oncology Group. Doxorubicin, cyclophosphamide, and paclitaxel with or without bevacizumab in treating patients with lymph node-positive or high-risk, lymph node-negative breast cancer [ClinicalTrials.gov identifier NCT00433511]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 Oct 12]
40. Hoffmann-La Roche. BEATRICE study: a study of Avastin (bevacizumab) adjuvant therapy in triple negative breast cancer [ClinicalTrials.gov identifier NCT00528567]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 Oct 12]
41. National Surgical Adjuvant Breast and Bowel Project (NSABP). BETH study: treatment of HER2 positive breast cancer with chemotherapy plus trastuzumab vs chemotherapy plus trastuzumab plus bevacizumab [ClinicalTrials.gov identifier NCT00625898]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 Oct 12]
42. National Surgical Adjuvant Breast and Bowel Project (NSABP). A clinical trial comparing the combination of TC plus bevacizumab to TC alone and to TAC for women with node-positive or high-risk node-negative, HER2-negative breast cancer [ClinicalTrials.gov identifier NCT00887536]. US National Institutes of Health, ClinicalTrials. gov [online]. Available from URL: http://www. clinicaltrials.gov [Accessed 2011 Oct 12]
43. Mancuso MR, Davis R, Norberg SM, et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 2006 Oct; 116 (10): 2610-21 (Pubitemid 44511625)
44. Ebos JM, Lee CR, Cruz-Munoz W, et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009 Mar; 15 (3): 232-9
45. Paez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009 Mar; 15 (3): 220-31
46. Miles D, Harbeck N, Escudier B, et al. Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials. J Clin Oncol 2011 Jan; 29 (1): 83-8
47. Schneider BP, Sledge Jr GW. Anti-vascular endothelial growth factor therapy for breast cancer: can we pick the winners? J Clin Oncol 2011; 29: 2444-7
48. Gerber B, Eidtmann H, Rezai M, et al. Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 686 triple-negative primary breast cancers: seconday endpoint analysis of the GeparQuinto study (G BG 44) [abstract no. 1006]. J Clin Oncol 2011; 29 Suppl. 15
49. Schneider BP, Wang M, Radovich M, et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG2100. J Clin Oncol 2008 Oct; 26 (28): 4672-8